A Repeatable and Consistent Selection Model - Twice a Year - 6 Month Programme
Many innovative ventures don't get access to the appropriate opportunities in their early stages due to lack of funds, and professional investors tend to favour business models with a longer track record. However, there is an incredible pool of talent with unexpressed potential and we aim to bridge promising companies to help them navigate the funding, 'valley of death'.
By selectively investing in these companies, and by diversifying into a portfolio across different fields within the digital health vertical, we endeavour to provide our investors with early winners and favourable returns.
An expert panel of reviewers from the NHS, DH.L and MedCity, is convened to validate the science and technology behind the shortlisted applicants.
RYSE will sign standard heads of terms, gain access to company data rooms, and carry out a deep due diligence. We compile and retain a detailed company report and due diligence folder for each potential investee company.
RYSE seeks to invest in early stage companies (seed stage up to and beyond Series A) to support them in their next phase of growth. Some of these companies may already have traction in the market and be revenue generating, and are typically looking to raise between £250,000 and £5,000,000.
Our aim is to provide investors with capital appreciation from a diversified portfolio of investments across early stage digital health companies.
We address an investment gap, often overlooked by institutional and professional investors, to enable investors to benefit from a highly diversified portfolio effect without compromising on due diligence.